Fosfructose (Questcor).

Title

Fosfructose (Questcor).

Creator

Folkesson H G

Publisher

IDrugs : the investigational drugs journal

Date

2001
2001-12

Description

Fosfructose is a cytoprotective natural sugar phosphate under development by Questcor (formerly Cypros) for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions. It is in phase III trials for sickle cell anemia [309234] and is in phase II/III trials for cardiovascular ischemia resulting from bypass surgery [337683]. The company has also commenced preclinical trials of fosfructose for asthma [337683]. In September 1999, the FDA granted fosfructose Fast Track designation for the treatment of the acute complications associated with coronary artery bypass graft surgery [340368].

Rights

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

Pages

1401–1407

Issue

12

Volume

4

Citation

Folkesson H G, “Fosfructose (Questcor).,” NEOMED Bibliography Database, accessed November 28, 2022, https://neomed.omeka.net/items/show/5402.

Social Bookmarking